Press Releases | Investor Relations | Eledon Pharmaceuticals, Inc.

10/29/2024	Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
10/29/2024	Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
09/11/2024	Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
09/04/2024	Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
08/14/2024	Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
07/29/2024	Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
07/02/2024	Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
06/03/2024	Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
05/09/2024	Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
05/09/2024	Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress